SLP:NASDAQSimulations Plus, Inc. Analysis
Data as of 2026-06-30 - not real-time
$18.38
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Simulations Plus (SLP) is currently trading at $18.38, marginally above its DCF‑derived fair value of $18.22, indicating a slight premium. The stock’s 20‑day SMA ($17.21) sits below the market price, while the 50‑day and 200‑day SMAs ($15.82 and $15.84) are well underneath, suggesting a short‑term upward bias. Momentum indicators are supportive: RSI is at 68.5 (near‑overbought), MACD shows a bullish crossover with a positive histogram, and volume is on an increasing trend. The recent definitive agreement to be acquired by Altaris for $18.50 per share adds a 26% premium to the 60‑day VWAP, providing a concrete catalyst for upside.
Fundamentally, the company reports strong operating cash flow ($24.4 M) and a healthy cash pile ($41.8 M) versus modest debt ($0.5 M), but profitability remains weak with a negative net profit margin and ROE of –38.8%. Volatility is elevated (50% 30‑day) and beta (1.26) exceeds the market, flagging higher systematic risk. Ongoing securities‑law investigations and class‑action scrutiny introduce additional uncertainty. Overall, the blend of a cash‑out acquisition premium, bullish technicals, and solid liquidity offsets the earnings volatility and regulatory headwinds.
Fundamentally, the company reports strong operating cash flow ($24.4 M) and a healthy cash pile ($41.8 M) versus modest debt ($0.5 M), but profitability remains weak with a negative net profit margin and ROE of –38.8%. Volatility is elevated (50% 30‑day) and beta (1.26) exceeds the market, flagging higher systematic risk. Ongoing securities‑law investigations and class‑action scrutiny introduce additional uncertainty. Overall, the blend of a cash‑out acquisition premium, bullish technicals, and solid liquidity offsets the earnings volatility and regulatory headwinds.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 9/10
Key Factors
- Acquisition premium of $18.50 cash per share
- Bullish technical setup (RSI, MACD, SMA crossovers)
- Increasing volume supporting price momentum
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Pending regulatory and shareholder approvals for the Altaris deal
- Potential impact of securities‑law investigations
- Strong cash position offsetting operating losses
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Uncertainty about post‑acquisition integration and strategic direction
- Historical earnings volatility and negative ROE
- Sector exposure to healthcare software regulatory changes
Key Metrics & Analysis
Financial Health
Revenue Growth8.30%
Profit Margin-77.96%
P/E Ratio20.3
ROE-38.84%
ROA3.81%
Debt/Equity0.38
P/B Ratio2.8
Op. Cash Flow$24.4M
Free Cash Flow$17.2M
Industry P/E25.9
Technical Analysis
TrendNeutral
RSI68.5
Support$15.29
Resistance$18.57
MA 20$17.21
MA 50$15.82
MA 200$15.84
MACDBullish
VolumeIncreasing
Fear & Greed Index89.91
Valuation
Fair Value$18.22
Target Price$17.25
Upside/Downside-6.15%
GradeOvervalued
TypeBlend
Risk Assessment
Beta1.26
Volatility50.32%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.